Neurosurgery medical robot Remebot for the treatment of 17 patients with hypertensive intracerebral hemorrhage

Objective To verify the minimally invasive surgical approach and therapeutic effects of using the medical neurosurgery robot Remebot to treat hypertensive intracerebral hemorrhage (HICH). Methods Clinical data for 17 HICH patients were analyzed retrospectively. Hematoma evacuation and tube drainage...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The international journal of medical robotics + computer assisted surgery 2019-10, Vol.15 (5), p.e2024-n/a
Hauptverfasser: Wang, Tao, Zhao, Quan‐Jun, Gu, Jian‐Wen, Shi, Tie‐Jun, Yuan, Xujun, Wang, Jia, Cui, Shao‐Jie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective To verify the minimally invasive surgical approach and therapeutic effects of using the medical neurosurgery robot Remebot to treat hypertensive intracerebral hemorrhage (HICH). Methods Clinical data for 17 HICH patients were analyzed retrospectively. Hematoma evacuation and tube drainage using Remebot frameless stereotaxic techniques were performed for all patients, and urokinase was injected into the hematomas after the operations. Results Robot‐assisted stereotactic techniques can accurately guide hematoma punctures, and no deaths occurred among these patients. The average positioning error was 1.28 ± 0.49 mm. The average drainage duration was 3.4 days. The 3‐month postoperative follow‐up revealed improved neurological functions and quality of life for all patients. Conclusions The medical neurosurgery robot Remebot is minimally invasive, has high positional accuracy, and facilitates surgical planning according to the shape of the hematoma. Therefore, robot‐assisted surgery using Remebot represents a safe and effective treatment method for hematoma evacuation and tube drainage in HICH patients.
ISSN:1478-5951
1478-596X
DOI:10.1002/rcs.2024